[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 481205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 53, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1111627, "exercisedValue": 0, "unexercisedValue": 901500}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 574704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter P. Pfreundschuh CPA", "age": 54, "title": "CFO & Treasurer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 49, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 72, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Dugan", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Norman D.  LaFrance FACNP, FACP, M.D.", "age": 75, "title": "Chief Development Officer", "yearBorn": 1948, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.85, "open": 14.72, "dayLow": 13.95, "dayHigh": 15.0, "regularMarketPreviousClose": 14.85, "regularMarketOpen": 14.72, "regularMarketDayLow": 13.95, "regularMarketDayHigh": 15.0, "beta": 0.694, "forwardPE": -28.056604, "volume": 189830, "regularMarketVolume": 189830, "averageVolume": 252210, "averageVolume10days": 158430, "averageDailyVolume10Day": 158430, "marketCap": 662752896, "fiftyTwoWeekLow": 4.69, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 7.6578107, "fiftyDayAverage": 13.7778, "twoHundredDayAverage": 13.4534, "currency": "USD", "enterpriseValue": 586221440, "profitMargins": -0.28439, "floatShares": 27071271, "sharesOutstanding": 44569800, "sharesShort": 4170638, "sharesShortPriorMonth": 4190440, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0936, "heldPercentInsiders": 0.12267, "heldPercentInstitutions": 0.6946, "shortRatio": 14.81, "shortPercentOfFloat": 0.11229999, "bookValue": 2.139, "priceToBook": 6.9518466, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -24613000, "trailingEps": -0.56, "forwardEps": -0.53, "pegRatio": 0.25, "enterpriseToRevenue": 6.774, "enterpriseToEbitda": -21.709, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "gmtOffSetMilliseconds": -14400000, "currentPrice": 14.87, "targetHighPrice": 26.0, "targetLowPrice": 11.0, "targetMeanPrice": 20.8, "targetMedianPrice": 21.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 77806000, "totalCashPerShare": 1.746, "ebitda": -27004000, "totalDebt": 1274000, "quickRatio": 2.3, "currentRatio": 2.916, "totalRevenue": 86546000, "debtToEquity": 1.336, "revenuePerShare": 1.978, "returnOnAssets": -0.12501, "returnOnEquity": -0.24611, "freeCashflow": -5677125, "operatingCashflow": -12553000, "revenueGrowth": 0.099, "grossMargins": 0.88625, "ebitdaMargins": -0.31202, "operatingMargins": -0.42938, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]